Early Stage Life Science Investors Converge on Boston

Monday, March 24th, 2014 - The State Room, Boston, MA

The RESI conference will be one of the more unique events in the life sciences space this coming year. This full-day investor partnering conference is groundbreaking in that it is focused on redefining the investor landscape in early stage life sciences. The life science investor landscape has changed; venture capital has left a void and there is a plethora of new entities entering the space with capital to allocate.
 
This conference has assembled these players - Senior decision-makers from some of the largest pharmaceutical & device companies, patient groups, philanthropic organizations, investment banks, and family offices will all be joining the action on March 24th. The conference will also have representation from next-generation technology transfer, licensing and funding experts, and there will be a series of free workshops. We urge all of our members to take a look at the program, and to take some time out to reeducate themselves regarding the new landscape unfolding in the life science investor arena.

Registration and sponsorship information is available at www.resiconference.com.

For any inquires please reach out:

Maximilian Klietmann 
Partner / VP of Marketing

Life Science Nation (LSN)
9B Hamilton Place

Boston, MA, 02108
Office: 617.600.3076 ext. 1005
Email: [email protected]com

Suggested Articles

VistaGen responded to the failure of the ketamine-line drug by vowing to review all the data before deciding on next steps.

Exicure is set to receive $25 million upfront to apply its spherical nucleic acid technology to two collaborative programs. 

Dewpoint Therapeutics is teaming up with Bayer on new drugs for a pair of neglected fields: heart disease and women’s health.